图1. 激酶催化的ATP介导的磷酸化反应过程。
图1. FDA批准小分子激酶抑制剂药物年份数量图。
图2. 部分FDA批准的激酶抑制剂药物分子结构。
图3. 激酶抑制剂常见的芳香杂环结构。
[1] Manning, G. et al. The protein kinase complement of the human genome. Science. 2002, 298, 1912–1934.
[2] Cohen, P. The regulation of protein function by multisite phosphorylation — a 25 year update. Trends Biochem. Sci. 2000, 25, 596–601.
[3] Manning, G., et al. The protein kinase complement of the human genome. Science. 2002, 298, 1912–1934.
[4] Muller, S. et al. The ins and outs of selective kinase inhibitor development. Nat. Chem. Biol. 2015, 11, 818–821.
[5] Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res. 2020, 152, 104609.
[6] Green, K. N. et al. To Kill a Microglia: A Case for CSF1R Inhibitors. Trends in Immunology. 2020, 41, 771–784.
[7] Imatinib Mesylate. The American Society of Health-System Pharmacists.
[8] Wu, P. et al. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015, 36, 422-439.
[9] Keating, J. A. et al. Phosphorylation events during viral infections provide potential therapeutic targets. Rev. Med. Virol. 2012, 22, 166–181.
[10] García-Cárceles, J. et al. Kinase Inhibitors as Underexplored Antiviral Agents. J Med Chem. 2022, 65, 935–954.
[11] Blake, S. et al. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin. Immunol. 2008, 127, 330–339.
[12] Naik, R. R. et al. Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19. Front. Pharmacol. 2022, 13, 806568.
2025-01-23
2025-01-17
2025-02-12
2025-02-27
2025-01-22
2025-01-20
2025-02-03
随着科技的快速发展,数字化转型已成为推动医药商品供应链管理进步的关键力量。本文深入分析了数字化转型的理论基础及其在医药商品供应链管理中的实际应用,旨在揭示其对效率提升和成本优化的积极影响。数字化转型理论为医药供应链的革新提供了理论支持,通过信息技术整合资源,实现了信息流、物流与资金流的无缝对接。在医药商品供应链管理中,数字化转型主要体现在供应链协同、预测与决策支持、智能物流等方面。通过构建信息化平台,并强化供应商、生产商、分销商与消费者之间的信息共享,不仅能够提高响应速度,还能降低库存水平、减少运营成本。本文强调了数字化转型对医药商品供应链管理的重要影响,并对未来的发展趋势进行了展望。随着新技术的不断涌现,医药供应链将更趋向于智能化和个性化,企业需持续跟进技术进步,以应对日益复杂的市场环境,实现可持续的竞争优势。
作者:韦颖、厉欢
评论
加载更多